Infinity Pharmaceuticals, Inc.
INFIQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -20.25% | 34.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -20.25% | 34.62% | |||
| Cost of Revenue | 10.41% | -13.66% | |||
| Gross Profit | -14.43% | 17.55% | |||
| SG&A Expenses | -36.84% | 112.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.54% | 21.40% | |||
| Operating Income | 12.05% | -20.64% | |||
| Income Before Tax | 9.86% | -19.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.86% | -19.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.86% | -19.66% | |||
| EBIT | 12.05% | -20.64% | |||
| EBITDA | 12.17% | -20.89% | |||
| EPS Basic | 10.28% | -19.55% | |||
| Normalized Basic EPS | 10.36% | -19.50% | |||
| EPS Diluted | 10.28% | -16.40% | |||
| Normalized Diluted EPS | 10.36% | -19.50% | |||
| Average Basic Shares Outstanding | 0.53% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.53% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||